University of California San Francisco
Give to UCSF
Companies claim there’s bad stuff in our homes and bodies, and we should pay to purge it. What’s worth worrying over?
As a worldwide shortage of contrast dye for medical imaging continues, a new UCSF research letter in JAMA quantified strategies to safely reduce dye use in computed tomography (CT) by up to 83%. CT is the most common use for the dye.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting.
Eric J. Small, MD, was announced as one of the winners of the 10th annual Giants of Cancer Care® awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.
Natalia Jura, an associate professor in the Department of Cellular and Molecular Pharmacology and an investigator at the UCSF Cardiovascular Research Institute, is the 27th recipient of the annual Byers Award.
Nevan Krogan, PhD, director of UCSF’s Quantitative Biosciences Institute, examines in detail the effects of a handful of genes that seem to play an outsize role in a wide array of diseases.
Wei Gordon was among nine finalists in the sixth annual UCSF Grad Slam, held March 31 – after a two-year hiatus due to the pandemic – competing to inform and entertain with three-minute talks based on their own research.
Brain tumor patients survived longer when treated aggressively with surgery, radiation and chemotherapy. Now, a UCSF study underscores the critical role of genomic profiling in diagnosing and grading brain tumors.
Leading UCSF cancer researchers will present at this year’s annual meeting of the American Association for Cancer Research conference, held April 8-13, 2022, in New Orleans, on topics such as updates on cancer’s environmental factors, targetable protein interactions, and effects on immune metabolism.
UCSF, in collaboration with the Quantum Leap Healthcare Collaborative (QLHC) and the U.S. Food and Drug Administration (FDA), has developed the OneSource system to seamlessly integrate clinical care and research data.
UCSF’s Division of Hematology-Oncology is welcoming Krishna Komanduri, MD, as division chief of Hematology-Oncology at UCSF Health. Komanduri is an international leader in the fields of hematology-oncology, transplantation, and cellular immunotherapy. He will start at UCSF on July 1.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
UCSF researchers found that cancers from different parts of the body are immunologically similar to one another. They described 12 classes of "immune archetypes" to classify cancer tumors, which can provide unique strategies for enhancing patients’ choice of cancer immunotherapies.
For patients with skin cancer & facial sarcoma, reconstructing the face with skin grafted from the leg may result in poor color match. A new technique pioneered by UCSF surgeons uses pigmented tissue to achieve a better match.
Helen Diller Family Cancer Research Building Experts from UCSF Health will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most
The UCSF initiative aims to increase the effectiveness and availability of chimeric antigen receptor T-cell (CAR T) therapy for lymphoma patients.
Last month, Hani Goodarzi received a $50,000 award for his work in the early detection of cancer and identification of therapeutic targets in cancer metastasis.
A groundbreaking national study led by UCSF finds that treating anal cancer precursor lesions reduces cancer risk for people with HIV.
A new prostate cancer test developed by UCSF and UCLA detects cancer cells that have spread to lymph nodes both inside and outside the pelvis.
Glioblastoma is the most common malignant brain tumor and among the most treatment-resistant cancers. In the last 15 years, numerous attempts to develop new drugs for glioblastoma have failed.
Researchers at UCSF and UC San Diego have mapped out how hundreds of mutations involved in two types of cancer affect the activity of proteins that are the ultimate actors behind the disease.
Researchers at UCSF have gained insight into how cancer cells proliferate despite a myriad of stresses.
Taking a page from computer engineers, biologists are trying their hands at programming cells – by building DNA circuits to guide their protein-making machinery and behavior.
